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Like all other areas of transplantation, vascularized
composite allografts (VCA) has the capacity to trans-
form the lives of patients, for the better or for the
worse. It is this duality that mandates VCA be per-
formed in centers prepared for the intricacies accompa-
nying other transplant procedures. Similarly, the com-
plexities of VCA require that the procedures be driven
by surgeons and physicians with experience in the mul-
tidisciplinary management of immunocompromised
postsurgical patients. Furthermore, the grafts should
be considered as organs rather than tissues from a
regulatory and a biological standpoint. The ASTS sup-
ports the field of VCA and has demonstrated its sup-
port and leadership by actively formulating a strategy
for its systematic development. The goal of this doc-
ument is to provide a framework for the prospective,
thoughtful realization of VCA in the United States from
the American Society of Transplant Surgeons (ASTS)
perspective.
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Introduction
Vascularized composite allografts (VCA) (a.k.a. composite
tissue allotransplantation) has been introduced as an op-
tion for limb replacement and reconstruction of major tis-
sue defects. VCA refers to the transplantation of nonautol-
ogous tissues (i.e. skin, muscle, tendon, nerve and bone)
as a functional unit to reconstruct defects that cannot be
reconstructed with autologous tissues. To date, over 70
patients have received a VCA worldwide (1). At the time
of this submission 10 patients have received hand(s) and 2
have received face transplants in the United States. To the
best of our knowledge, US programs have performed VCA
under the infrastructure delineated in this document (2,3).
Like other transplants, VCA has the capacity to transform
the lives of patients, for the better and for the worse.
It is this duality that mandates that VCA be performed
at centers capable of appropriately responding to the in-
evitable contingencies that have been described in organ
transplantation. Centers moving forward with VCA should
demonstrate the same depth and breadth of services cur-
rently mandated by the Transplant Final Rule for solid organ
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transplantation (4). The ASTS believes that creating stan-
dards for VCA under the definition of Organs under the Final
Rule and under the definition of Human Organs under Sec-
tion 301 of NOTA will provide the necessary framework
to promote the highest quality practice with consistency,
safety and professionalism. Additionally, it would provide
assurance that all centers performing these transplants
follow similar governs. The ASTS recognizes the need of
outlining considerations for the wide and safe implemen-
tation of VCA. As such, the goal of this document is to
propose a structured framework for the development of
a prospective thoughtful realization of VCA in the United
States.
Background
On May 1, 2008 the ASTS responded to the Request for
Information put forward by the Health Resources and Ser-
vices Administration on the March 3, 2008 Federal Reg-
ister regarding VCAs (5). The ASTS supported the inclu-
sion of VCAs within the definition of organs recovered by
regulations governing the Organ Procurement and Trans-
plantation Network (OPTN) and supported adding VCA to
the definition of human organs recovered by the National
Organ Transplant Act. Due to the fact that recovery of
VCAs from deceased donors entail direct interaction with
Organ Procurement Organizations (OPOs) in connection
with recovery of solid organs, the ASTS strongly believes
it is appropriate that the OPTN’s regulatory oversight be
extended to VCAs. This stems from the recognition that
as VCA transplantation expands, it will be necessary to
have a standard assessment of the safety and quality of
the graft. Additionally, an acceptable algorithm for deter-
mining the process of recovery of VCAs from deceased
donors must be coordinated with teams obtaining other
organs for transplantation. The ASTS also identifies other
advantages; it would provide assurance that all centers per-
forming these transplants follow similar governs. Addition-
ally, the relationships with the OPO’s would be facilitated,
donors could be considered over a wide geographic area,
it would be helpful when questions in the government or
the public arise, and it would facilitate acceptance from the
public for donation of VCAs. VCAs share characteristics
and present differences compared to conventional organ
transplants. Similarities include that all (1) involve vascu-
larized allografts, (2) are recovered from a human donor
as an anatomical/structural unit, (3) are transplanted into
a human recipient as an anatomical/functional unit, (4) are
minimally manipulated, as defined by the FDA in Title 21
CFR 1271.3, (5) are not combined with another article such
as a device, (6) are used fresh and not cryopreserved, (7)
are susceptible to ischemia and therefore not stored tem-
porarily or for a long term-–for example, not more than 36 h
and (8) are susceptible to allograft rejection thus requiring
the recipient to take immunosuppression. VCA differs from
most conventional organ transplants in that the grafts, (i)
are transplanted to enhance quality of life, (ii) are external
and visible, and have the potential of being identifiable after
donation, (iii) require nerve function and (iv) include tissues
from three germ layers.
Program Organization
Since its beginning, clinical transplantation has grown in
close association with research. Today, transplantation con-
tinues being a unique setting to study immunology, and
transplant-related applications to improve patient care. As
with other transplants, VCA has its unique challenges and
considerations. Thus, the following draft provides a pro-
posal for a VCA program in the United States with special
reference to the research nature of the field at this time.
General Program Organization
A VCA program from its inception should target an inter-
disciplinary approach conducted within a UNOS/OPTN ap-
proved Transplant Center with laboratory, clinical and hu-
man resources dedicated to this effort both physically and
administratively. Integration between clinical care and re-
search is ideal. The interdisciplinary team should include
surgical and medical physicians (reconstructive surgeon,
transplant surgeon and medical transplant physician),
nurse coordinator, pathologist, pharmacologist, mental
health provider, rehabilitation medicine, tissue typing spe-
cialists, data entry personnel, infectious disease specialist,
social worker and basic laboratory personnel. Regular
meetings should include planning and budgetary matters.
In addition, patient selection, posttransplant follow-up, mor-
bidity and mortality and scientific studies should be con-
ducted such that the team is integrated into patient care
and program development. A computer database should
be used for patient and protocol data management.
Screening and Consenting Procedures
Given the investigational nature of the field, all VCA pro-
grams should be subject to institutional regulations for the
conduct of human research and all patients should be en-
rolled in Institutional Review Board approved protocols. As
such, every patient should undergo a research consenting
process. Due to the innovative nature of the procedure,
candidates may demonstrate enthusiasm to take the risk
of receiving a VCA to improve their quality of life but would
not be suitable candidates for the procedure. Alternatively,
candidates may be medically appropriate but lack evidence
of compliance, social support or a thorough follow-up com-
mitment. Thus, the importance of patient selection and
a multidisciplinary evaluation process cannot be overem-
phasized. Patient recruitment should be initiated with edu-
cation about research and standard of care/nonresearch
options, research patient responsibilities and an infor-
mation package should be provided to the candidates.
14 American Journal of Transplantation 2011; 11: 13–17
Implementation of VCA in the United States
Information in the package should include up to date na-
tional and international outcomes and statistics in VCA,
standard of care options such as prosthesis, reconstruction
with autologous-tissue, rehabilitation, immunosuppressive
medications and their complications and an overview of
the transplant process. All patients should be made aware
of the concept of nonobligating participation and be given
sufficient time to think about their research participation.
Organ Procurement Organization
A required and invaluable component for the success of
VCA both in terms of development and clinical results is
the participation and expertise of the OPO community.
With the assistance of the VCA transplant center, the
OPO should develop standardized policies and procedures
for the evaluation of the potential VCA donor, informed
consent for VCA donation, donor management and graft
procurement. Procurement procedures for VCA grafts
should be integrated into the multiorgan procurement pro-
cess without jeopardizing other organs potentially being
procured for transplant. In addition to the knowledge that
their involvement will help the development of VCA and
potentially improve the lives of our patients, participating
OPO’s should be rewarded for their service. The VCA
should be considered an additional organ procured and
thus count toward the OPO’s yield (organs per donor).
Also, graft-specific acquisition costs should be determined
and the OPO should be fully reimbursed for their expenses
and efforts.
Evaluation and Listing
All patients should undergo an extensive and thorough
medical, social and psychological evaluation process.
These include one-on-one teaching sessions to cover spe-
cific terminology and general transplant information. In ad-
dition to the medical evaluation, all patients should un-
dergo psychosocial appraisals after the informed consent
has been signed. The purpose is multidimensional with
specific focus on the candidate’s suitability for the protocol.
Special consideration to the receipt and potentially loss of a
visible transplant should be carefully examined. Essentially
all recipients have experienced rejection episodes and the
current rejection rate of 85% within the first year should be
addressed (6). Psychological support should be available at
all times and alternatives to failure such as returning to a
prosthetic device after hand transplantation or death after
a face transplant should be well outlined.
Funding is mainly from federal sponsors. As a research
field, of importance is to examine financial susceptibilities
and assure resources to warranty quality of care. A
well-delineated plan should be in place for protocol-related
expenses and the patient’s responsibilities for the other
costs. The candidate must be aware about the need
of medication and regular medical care for as long as
he/she has the transplant. Social work assessment and
involvement in ongoing bases is an essential aspect of the
process.
After the evaluation is completed, each case should be
reviewed in a multidisciplinary format. The requirements
for listing a patient should be similar to those for other
transplant candidates. This includes documentation of an
evaluation by a transplant physician and surgeon, a recon-
structive surgeon, a social worker, financial clearance, two
separate blood-type determinations, approval for listing by
the transplant team’s multidisciplinary ‘listing committee’,
and completion of all Centers for Medicare and Medicaid
Services (CMS) documentation requirements. If the can-
didate is approved to move forward with the transplant,
the OPO should be notified. Thereafter, the transplant co-
ordinator should maintain the listing requirements on site.
Periodic reevaluations should be required to maintain med-
ical fitness and to keep the candidates aware of the field
and protocol/outcomes development.
Criteria for VCA Transplant Members
Each program should be under the leadership of a Program
Director. Given the diverse surgical requirements for VCA,
the Program Director need not be the primary operating
surgeon, but rather should have expertise in the aggregate
application of VCAs. In addition, the VCA program should
identify a qualified primary surgeon with expertise in mi-
crosurgical reconstruction, prior experience in VCA, or in
lieu of actual VCA experience, extensive experience in the
applicable reconstructive procedure as required (e.g. hand
replantation and facial reconstruction).
The Surgical Director and the Primary and Recovery Sur-
geon should have a current US medical license and be
credentialed to practice at the OPTN member transplant
center hospital.
An immunosuppression team should support the surgi-
cal team, both of who should perform posttransplant
follow-up. Transplant immunology and immunosuppres-
sion expertise should reside in at least one team member,
ideally the Program Director. This will be evidenced by
completion of an approved transplant fellowship in a med-
ical or surgical specialty and current qualifications as a
transplant physician or surgeon by UNOS criteria. Evi-
dence of cooperative planning and posttransplant care
for the patients from the team members cannot be
overemphasized.
Policies need to be in place at the transplant hospital to
incorporate the new program into the existing safety poli-
cies. The specific policies dealing with donor and recipient
blood types A, B and O, HLA, cross-match identification
and compatibility, the organ/tissue chain of custody, identi-
fication and subsequent disposal also need to be covered
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as does the identification and disposition of the vessels
that may accompany the VCA.
Procurement
Each program should work closely with the respective
OPO. Planning meetings with members of the organiza-
tion should be scheduled to coordinate the logistical and
administrative aspects of the process.
Given the unique and novel components of VCA, OPOs
should have a trained designated requestor for VCA. Poli-
cies should be in place for vascularized tissue recovery and
transport along with a confirmation of the qualifications
of the recovery surgeon. At this point, a memorandum of
understanding describing the bilateral agreement between
the transplant center and the OPO or some similar ex-
plicit document should be in force to provide the neces-
sary framework to establish a common line of action with
respect to VCA. In-services should be developed by the
VCA team to provide information about donor and recipi-
ent screenings, selection criteria, order of the VCA procure-
ment and the consenting process. The OPO should have
an identified person for communication of donor cultures
or pathology results. All appropriate behavioral and safety
policies for organ recovery shall apply to VCA recovery. The
use of anatomically appropriate prosthetics for use on the
deceased postprocurement should be available and offered
to the consenting family member. Periodic reevaluation of
the process is recommended.
Donor Selection Criteria
OPTN/UNOS approved criteria should be developed for
all VCA donors and the screening guidelines should in-
clude parameters developed for other organ transplants
(7). Donor criteria and donor–recipient matching parame-
ters should include ABO type, and size compatibility with
the recipient. Pending the addition of the specifics for the
different tissue risks infections, matching of infectious risks
should follow those established for organ transplantation
(7). Traumatic injuries will be critical information for VCA
donor acceptance and allocation. Consideration regarding
distance between the donor hospital and the transplant
center are important as this related to ischemic time. At
this time, exclusion of children—defined by radiographic
evidence of growth plate nonfusion—as VCA donors is
recommended due to limited systematic data in VCA.
However, as the field develops the inclusion of children
will require following established considerations for pedi-
atric donors in other organs with additional VCA-specific
factors.
Listing criteria should also comprise amount and type of
tissue to be included. It is anticipated that organ offers will
follow the similar processes as other organ allocation.
Expanded donor criteria remain undefined. Arthritis, prior
musculoskeletal surgeries, skin cancer excision and prior
facial procedures should be considered.
Due to the uniqueness of VCA, involvement of the trans-
plant team is necessary from the early planning stages.
These include, but are not be limited to, dry runs of the
procurement in a laboratory, pretransplant strategy ses-
sions to deal with public relations matters such as protec-
tion of donor confidentiality, society and public education
and participation of prosthetists for deceased donor recon-
struction.
Consent for Donation
The informed consent process should reflect the research
nature of the field. As for other organs procured for trans-
plantation, consent should be obtained from the appropri-
ate family member or designated surrogate by qualified
OPO personnel. As with other organs, there should be
neither financial benefit nor added expense for the donor
family. The process should be organ specific and purpose
specific; general consent for donation of everything that
can utilize is insufficient. It should be clearly presented
that VCA grafts are considered ‘organs’ for clinical trans-
plantation under a research protocol.
Proper informed consent requires a discussion of the pro-
curement procedure, the potential benefits, risks and alter-
natives for the recipient and the impact on the deceased
donor. Specifically, the person providing consent should
understand how the appearance of the donor will be al-
tered by the procurement procedure and if, how, and to
what degree that appearance will be restored.
Theoretical Donor Allocation
In solid organ transplantation, the relative shortage of
donors compared to candidates has led to the need to
develop allocation policies. While the numbers of poten-
tial candidates for VCA is small initially, we believe spe-
cific allocation policies should be developed prospectively.
Such policies are necessary to operationalize VCA nation-
ally given the number for OPO’s and centers. Addition-
ally, established allocation policies promote transparency
of processes for all involved, including the public. Common
frameworks for organ allocation are based on principles in-
cluding Equity, Utility, Urgency and Benefit. Given the na-
ture of VCA, it is unlikely that measures of urgency and
benefit will provide a sufficiently robust framework for allo-
cation. Consequently, components of equity (e.g. waiting
time) and utility (e.g. matching for form and function) are
likely to predominate any VCA allocation system. Consis-
tent with the previous recommendations, we believe any
allocation system should be developed within the preex-
isting structure provided within the OPTN.
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Transplantation
The technical aspects involved to transplant different tis-
sues have rapidly evolved and are standard. Close mon-
itoring of both the reconstructive and immunological as-
pects are required. During the postoperative phase, rounds
should be conducted by the interdisciplinary team and a
thorough review of the condition of the transplant and med-
ication and doses should be recorded. Priority should be
placed on the patient’s education, identification of visible
changes in the skin, therapy and postoperative recovery.
A staff member should be available for the instruction of
the patients regarding the follow-up appointment, timing
and dosing of medications. Each patient should undergo
education by a pharmacist.
Rehabilitation medicine should work in close communica-
tion with the primary surgeon before and after surgery.
Therapy should be performed according to the VCA needs.
The therapists should participate in the preoperative eval-
uation and continue functional progress, needs and mod-
ify/advance therapy following each patient’s progress ac-
cording to the reconstruction.
Evidence-Based Evaluation of VCA
Organ transplantation has benefited from the systematic
collection of data and rigorous analysis. The NOTA specifi-
cally mandated such a process. In context of VCA, a simi-
lar registry should be developed to collect specific data so
that the state of the art can be shared within those work-
ing or approaching VCA. VCA should be included in the US
national database of statistics related to solid organ trans-
plantation. The Scientific Registry of Transplant Recipients
(SRTR) ‘covers the full range of transplant activity, from
organ donation and waiting list candidates to transplant re-
cipients and survival statistics’ (8). As such, VCA should be
included within the scope of work of the SRTR.
Conclusion
It is acknowledged that VCA is in its initial experimental
stages. Nonetheless, VCA has reached a phase where clin-
ical development is clearly appropriate and cost effective-
ness analyses are taking place. ASTS would like VCA to
develop in a scholarly, evidence-based fashion. Most im-
portantly, the field should advance focused on the care for
donors, donor families and recipients, and in doing so in-
sure the best outcomes for VCA recipients both present
and future.
Acknowledgments
The authors are appreciative to Dr. David Reich for his insightful comments.
The authors are thankful to the thoughtful discussions with the ASTS Coun-
cil. The authors are grateful of Katrina Crist, MBA, ASTS Executive Director,
Chantay Parks, ASTS Communications Director and the ASTS staff for the
invaluable support and leadership. The members of the ASTS VCA Ad Hoc
Committee are Linda Cendales, Darla Granger, Jon Jones, John Magee,
Timothy Pruett, Douglas Tadaki, David Levi and Suzanne Ildstad.
Disclosure
The authors of this manuscript have no conflicts of inter-
est to disclose as described by the American Journal of
Transplantation.
References
1. www.handregistry.com. Accessed March 3, 2010.
2. Amirlak B, Gonzalez R, Gorantla V et al. Creating a hand transplant
program. Clin Plast Surg 2007; 34: 279–289.
3. Siemionow M, Gordon C. Overview of guidelines for establishing
a face transplant program: A work in progress. Am J Transplant
2010; 10: 1290–1296.
4. Chapter I. Public Health Service, Department of Health and Human
Services. Subchapter K, Health Resources Development. Part 121:
Organ Procurement and Transplantation Network. Public Health,
Title 42.
5. Department of Health and Human Services. Health Resources and
Services Administration. Federal Register Vol 73, No. 42/Monday,
March 2, 2008: 11420–11422.
6. Petruzzo P, Lanzetta M, Dubernard J et al. The international registry
on hand and composite tissue transplantation. Transplant 2008;
86: 487–492.
7. OPTN/UNOS Policy 4–4.7. www.unos.org/PoliciesandBylaws2/
policies/pdfs/policy_16.pdf. Accessed March 3, 2010.
8. www.ustransplant.org/who.aspx. Accessed March 3, 2010.
American Journal of Transplantation 2011; 11: 13–17 17
